INTRODUCTION
1, 3, 4-Oxadiazoles are biologically active, synthetically useful and important heterocyclic compounds. Different classes of oxadiazole compounds possess an extensive spectrum of pharmacological activities such as antibacterial 1 , antimalarial 2 , anti-inflammatory 3 , antifungal 4 , anticonvulsant 5 , analgesic 6 antimycobacterial 7 , antitumor 8 , herbicidal 9 , vasodialatory 10 , cytotoxic 11 , hypolipidemic 12 , ulcerogenic 13 and antiedema 14 . Numerous thiazolidinone derivatives have shown significant pharmacological and biological activities 15 like sedative 16 , antiinflammatory 17 , antibacterial 18 , antifungal 19 , antitubercular 20 , anticancer 21 , hypnotic 22 , anti-HIV 23 and nematicidal 24 .
ANTIMICROBIAL ACTIVITY
The in vitro antimicrobial activity of newly synthesized compounds, 4-phenyl-9-(5-phenyl- [1, 3, 4 ]-oxadiazol-2-yl)-1,6-dithia-4,9-diaza-spiro-[4.4]-nonane-3,8-diones (4a-e) was determined using disc diffusion method 6 . The antibacterial activity was measured against two grampositive strains viz., Staphylococcus aureus and Bacillus subtilis and two gram-negative strains viz., Escherichia coli and Pseudomonas aeruginosa and expressed in terms of zone of inhibition in mm at concentration of 5 μg/disc. The antifungal evaluation was carried out against fungal organisms namely Candida albicans and Aspergillus niger at concentration of 5 μg/disc. Standard antibacterial drug Ciprofloxacin (5 μg/disc) and antifungal drug Fluconazole (5 μg/disc) were also tested under similar conditions against these organisms. Each experiment was done in triplicate and the average reading was taken.
The investigation of antibacterial screening data revealed that all the tested compounds exhibited significant and interesting biological activity, however with a degree of variation. According to the results (Table 1) , it is clear that, some of the compounds displayed excellent antimicrobial activity. Among the series of the screened compounds 4a-e, the compound 4e which contain 4-bromo phenyl ring system, against E. coli is highly active at 28 mm zone of inhibition which is equal to the standard drug Ciproflaxacin. The compound 4e towards C. albicans is also exhibited good antifungal activity at 24 mm zone of inhibition which is almost equal to the standard drug. The remaining compounds showed moderate to good activity against the test organisms. It is interesting to note that, none of the compound is inactive against all the tested microorganisms and this remarkable property may achieve to the compounds due to the two active pharmacophores (oxadiazole and thiazole) in a single molecular skeleton. 
EXPERIMENTAL
All reagents and solvents were used as purchased without further purification. Melting points were determined on a Fisher-Johns melting point apparatus and are uncorrected. Crude products were purified by column chromatography on silica gel of 60-120 mesh. IR spectra were obtained on a PerkinElmer BX series FT-IR 5000 spectrometer using KBr pellet. NMR spectra were recorded on a Varian 300 MHz spectrometer for 1 H NMR. The chemical shifts were reported as ppm down field using TMS as an internal standard. Mass spectra were recorded on a VG-Micromass 7070H spectrometer operating at 70 eV.
Synthesis of 2-chloro-N-(5-phenyl-[1,3,5]-oxadiazol-2-yl)-acetamide (2)
A mixture of 2-amino, 5-phenyl-1,3,4-oxadiazole (1) (0.01 mol) and chloroacetyl chloride (0.01 mol) was refluxed in triethyl amine (10 ml) for 4 h. After completion of the reaction (monitored by TLC), the resultant solution was cooled, the separated solid was filtered, dried and recrystallised from pet-ether to get pure
Synthesis of 2-benzylidene-3-(5-phenyl-[1,3,5]-oxadiazol-2-yl)-thiazolidin-4-one (3)
Compound 2 (0.01 mol) was treated with phenyl isocyanate (0.01 mol) at room temperature in presence of K 2 CO 3 (0.5 g) in acetonitrile (15 ml). The reaction mixture was refluxed on constant stirring for 6 h. After conventional work up, the product was purified by recrystallization from methanol to give pure 2-
Synthesis of 4-phenyl-9-(5-phenyl-[1,3,4]-oxadiazol-2-yl)-1,6-dithia-4,9-diaza-spiro-[4.4]-nonane-3,8-dione (4a-e)
An equimolar mixture of compound 3 (0.01 mol) and mercapto acetic acid (0.01 mol) was refluxed in dioxane for 7-9 h. After completion of the reaction (monitored by TLC), the reaction mixture was allowed to cool and was poured over crushed ice. The organic layer was extracted with ethyl acetate (20 ml), washed with 10% sodium bicarbonate solution (1 X 20 ml) and dried with anhydrous sodium sulphate. The solvent was removed under vacuum and residue was recrystallized from methanol to yield the corresponding 4-phenyl-9- -3-(5-phenyl-[1,3,5]-oxadiazol-2-yl) -[1,3,4]-oxadiazol-2-yl)-9-p-tolyl-1,6-dithia-4,9-diaza-spiro-[4.4]-nonane-3 -phenyl)-9-(5-phenyl-[1,3,4]-oxadiazol-2-yl)-1,6-dithia-4,9-diaza-spiro-[4.4]-nonane-3,8- 146.7, 143.7, 139.6, 136.7, 134.5 (2), 132.7 (2), 130.2, 128.7 (2), 123.4 (2), 78.7, 30.3, 26.3 -phenyl)-9-(5-phenyl-[1,3,4]-oxadiazol-2-yl)-1,6-dithia-4,9-diaza-spiro- Bromo-phenyl)-9-(5-phenyl-[1,3,4]-oxadiazol-2-yl)-1,6-dithia-4,9-diaza-spiro-[4.4]-nonane-3,8- 
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RESULTS AND DISCUSSION
The therapeutic importance of these rings prompted us to develop selective molecules in which a substituent could be arranged in a pharmacophoric pattern to display higher pharmacological activities. Thus we have designed and synthesized a series of novel 4-phenyl-9- 13 C NMR, mass spectral data and elemental analysis. Further the compounds 4a-e were used to evaluate their antimicrobial activity.
